Clinical Trial Update: A Long-Term Study on Safety of JNS001 in Adults With Attention-Deficit Hyperactivity Disorder [Phase 3]

View source ↗

Summary

A Phase 3 long-term safety study of JNS001 in adults with attention-deficit/hyperactivity disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• JNS001

Snippet

Sponsor: Janssen Pharmaceutical K.K. | Conditions: Attention-Deficit / Hyperactivity Disorder | Phase 3 | Status: COMPLETED